Time goes by and antibiotics linger on
Some time ago I stumbled on a fantastic article by Holloway discussing a new approach to treating multi-drug-resistant tuberculosis. The climax is: in Switzerland, England and New York, tuberculosis-related deaths started to decline decades before the introduction of streptomycin, which was the first antibiotic used against tuberculosis. Of course, the decline rate increased in the antibiotic era. However, make no mistake, if we were in a Batman movie, antibiotics would be Robin. Essential to the plot, but not the main character. That's it. The link between my random fact and the purpose of this post.
Why do so many physicians believe antibiotics are the main character in every patient with a possible or confirmed infection?
To make things worse, not only do tons of doctors think that way, but they also blindly believe that the more time Batman is on the screen, the better the movie. “Wait a minute Mister! We’re not like that! We’re among the top-ranked badass critical care docs evidence-based-culture-guided early de-escalation type of guys”. I gotta only one thing to say: Liar liar, pants on fire! Fortunately, I have some data to support my insults. A Canadian study showed a median duration of antibiotic treatment for bacteremia of 14 days. In the U.S., 50% of empirical antibiotics are continued in the absence of infection for more than 72h. A global survey showed that although there was substantial heterogeneity between ICUs, most cases of bacteremia (more than 80%) are treated for 8 days or more, and finally, just to exemplify, an observational study showed that 30% of antibiotic use was deemed unnecessary in a university hospital.
What causes us to behave like that?
Of course, there are tons of cognitive biases behind it, but mind’s misconceptions are not an excuse, especially when we have literature advocating in favour of the conscious use of antibiotics. Complicated urinary tract infection? No more than 7 days, sometimes 5 is enough. Pneumonia (community-acquired, hospital-acquired, ventilator-associated)? Go for less than 8 days. Uncomplicated Staph bacteremia? Shorter courses (10 days) do not impact on mortality. Even surgeons are realising that less is more, from appendicitis to other intra-abdominal infections. It's shameful to see surgeons using only 3 days of antibiotics while some intensivists are still using the lunar calendar to guide treatment duration. Ok, more NEJM-type-of-trials are still needed, but we can’t deny that for the most common ICU infections (intra-abdominal, pneumonia and urinary) all roads lead to shorter antibiotic courses. Why do we stop giving fluids after our patients are no more hypotensive (I won’t discuss fluid responsiveness here, but you got the idea) and we still keep injecting them with antibiotics when they get better? “Oh, because we’re afraid of recurrence”! Really? Every patient will have a recurrent infection if you stop antibiotics early? Seven days, fourteen days… Who invented this? Why not 4.5, 5.66 days? Why not the amount needed?
Antibiotics don’t replace good doctors. Indiscriminate antibiotic use is a reckless attitude that not only dramatically increases healthcare costs, but also puts our patients' lives in danger. This is not an “I’ll deal with it tomorrow” or “what difference one more day will do” type of thing. We already missed the bus.
But what can we do?
We can rely on evidence-based knowledge and self-discipline all doctors have, and with a pinch of goodwill and time, things will settle. Of course, this is a lie. Changes like this only come from the top down. But there is a light at the end of a vancomycin bottle. Antibiotic Stewardship Programmes might be the answer we were looking for. For more than two decades this idea of a multidisciplinary and multifaceted strategy aimed to ensure rational antibiotic use among other things has spread, and its benefit has been proven, from reducing costs to decreasing Clostridium difficile infection rates, with everything in between. This makes perfect sense. A multilevel intervention to solve a huge problem. It’s impossible to think we can overcome this issue with single-minded interventions like good doctors with some knowledge about antibiotic usage; there are too few of them. Like everything in critical care, this is a team effort.
Back to our tuberculosis discussion. It emphasises that in patient care, no magical molecule is the answer. Instead, it's part of a very complex and dynamic set of possible answers. Late at night, after reading this, I know you’ll evaluate your practice, but unfortunately, next morning things still will be the same, and I bet a beer you’ll have a patient receiving unnecessary antibiotics in your unity. I won’t judge you (I’m lying, I’m judging you). Bold actions require attitude. Maybe you weren’t aware of the evidence, maybe somebody told you antibiotics grow on trees, or maybe somebody in your anti-vaccine group told you multidrug-resistance is a lie. Now you know. We have the evidence, I’m telling you antibiotic costs A LOT of money (ok, some of them used to grow in nature), vaccines work and multidrug-resistance is real. Now, it is up to you.
Zoom On Bruno Tomazini
What is your top management tip?
Team work is the engine behind every ICU. Humbleness and respect are the invisible fuel. Respect your team, from the cleaning lady to head nurses. You need them more than you can imagine. And always, work hard and fear nothing.
What are your personal interests outside of work?
I love travelling, but since books and music are cheaper, I'm all eyes and ears.
Your favourite quote?
"Man is...a thinking erratum, that's what he is. Every season of life is an edition that corrects the one before and which will also be corrected itself until the definitive edition, which the publisher gives to the worms gratis." Machado de Assis
Daneman N, Rishu AH, Xiong W et al. (2016) Duration of antimicrobial treatment for bacteremia in Canadian critically ill patients. Crit Care Med, 44(2): 256-64.
Thomas Z, Bandali F, Sankaranarayanan J et al. (2015) Multicenter evaluation of prolonged empiric antibiotic therapy in adult ICUs in the United States. Crit Care Med, 43(12) 2527-34.
Corona A, Bertolini G, Ricotta AM et al. (2003) Variability of treatment duration for bacteraemia in the critically ill: a multinational survey. J Antimicrob Chemother, 52(5): 849-52.
Hecker MT Aron DC, Patel NP et al. (2003) Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med, 163(8): 972-8.
Sandberg T, Skoog G, Hermansson AB et al. (2012) Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial The Lancet, 380(9840): 484-90.
Peterson J, Kaul S, Khashab M et al. (2008) A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology, 71(1): 17-22.
Dimopoulos G, Matthaiou DK, Karageorgopoulos DE et al. (2008) Short-versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs, 68(13): 1841-54.
Micek ST, Ward S, Fraser VJ et al. (2004) A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest, 125(5): 1791-9.
Uranga A, España PP, Bilbao A et al. (2016) Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med, 176(9): 1257-65.
Pugh R, Grant C, Cooke RP et al. (2015) Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev, (8): CD007577.
Chong YP, Moon SM, Bang KM et al. (2012) Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse. Antimicrob Agents Chemother, 57(3): 1150-6.
Sawyer RG, Claridge JA, Nathens AB et al. (2015) Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med, 372(21): 1996-2005.
Park HC, Kim MJ, Lee BH et al. (2017) Randomized clinical trial of antibiotic therapy for uncomplicated appendicitis. Br J Surg, 104(13): 1785-90.
Aldeyab MA, Kearney MP, Scott MG et al. (2012) An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrobial Chem, 67(12): 2988-96.
Published on : Thu, 7 Dec 2017
Always in sight, always in mind Features Mindray believes the best way to predict the future is to create it. The revolutionary BeneVision N22/N19 is designed to optimize user experience by satisfying all your clinical demands. With visionary-stimulating...
FeaturesMindray BeneVision Central Monitoring System is a powerful and scalable solution providing for continuous, real-time surveillance across networks large and small. The system can display patient information from networked monitors, wireless transport...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...
The HAMILTON-C6 represents a new Generation of high-end ventilators. The combination of modularity, ease of use, mobility, and advanced features allows you to individualize your patient's ventilation therapy: - State-of-the-art ventilation modes for adult,...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...